Single low-dose tafenoquine combined with dihydroartemisinin–piperaquine to reduce Plasmodium falciparum transmission in Ouelessebougou, Mali: a phase 2, single-blind, randomised clinical trial

BACKGROUND: Tafenoquine was recently approved as a prophylaxis and radical cure for Plasmodium vivax infection, but its Plasmodium falciparum transmission-blocking efficacy is unclear. We aimed to establish the efficacy and safety of three single low doses of tafenoquine in combination with dihydroa...

Descripción completa

Detalles Bibliográficos
Autores principales: Stone, Will, Mahamar, Almahamoudou, Smit, Merel J, Sanogo, Koualy, Sinaba, Youssouf, Niambele, Sidi M, Sacko, Adama, Keita, Sekouba, Dicko, Oumar M, Diallo, Makonon, Maguiraga, Seydina O, Samake, Siaka, Attaher, Oumar, Lanke, Kjerstin, ter Heine, Rob, Bradley, John, McCall, Matthew B B, Issiaka, Djibrilla, Traore, Sekou F, Bousema, Teun, Drakeley, Chris, Dicko, Alassane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9042793/
https://www.ncbi.nlm.nih.gov/pubmed/35544095
http://dx.doi.org/10.1016/S2666-5247(21)00356-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9042793/
https://www.ncbi.nlm.nih.gov/pubmed/35544095
http://dx.doi.org/10.1016/S2666-5247(21)00356-6

Ejemplares similares